anticipated announcements - q1 2012, page-9

"Theres plenty of announcements from companies like that"
How many Antisense companies do we have in ASX?

Anyway,

Your only concern is the time it may take to get things moving.

ATL1101 for prostate cancer was in preclinical trial in 2007. It is not rapidfire, it is after 4 years of developments and we are at the Phase1/2 financing stage.

ATL1102 started in 2004 and developed to Phase 2. It is not just yesterday that it is being developed. It could be this year that it can be moved forward to Ph3 once the toxicology retest is done AND the Stem Cells mobilisation could be commercialised.

As I mentioned previously, with the worldwide attention given to 2nd Antisense drugs going to market this year, there will be more motivation for pharmas to get deals done faster compare to the previous 7 years when Antisense was just in its conceptual and research stage.

Unlike previous Antisense trial, a Pharma was doing DD as soon as ATL1103 Phase 1 was completed successfully. This did not happen before and can only proved that the antisense platform is gaining momentum in drug development.